Russell Investments Group
CLVS

Russell Investments Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Russell Investments Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-148,680
Closed -$401K – 3010
2021
Q4 		$401K Sell
148,680
-22,469
-13% -$83.1K ﹤0.01% 2507
2021
Q3 		$762K Hold
171,149
– – ﹤0.01% 2308
2021
Q2 		$992K Buy
171,149
+100,602
+143% +$589K ﹤0.01% 2318
2021
Q1 		$494K Buy
+70,547
New +$473K ﹤0.01% 2528
2019
Q1 		– Sell
-16,824
Closed -$302K – 3052
2018
Q4 		$302K Sell
16,824
-1,026
-6% -$21K ﹤0.01% 2488
2018
Q3 		$525K Sell
17,850
-13,183
-42% -$510K ﹤0.01% 2367
2018
Q2 		$1.41M Hold
31,033
– – ﹤0.01% 1940
2018
Q1 		$1.64M Buy
31,033
+10,154
+49% +$592K ﹤0.01% 1970
2017
Q4 		$1.42M Sell
20,879
-13,546
-39% -$947K ﹤0.01% 1977
2017
Q3 		$2.84M Buy
34,425
+28,223
+455% +$2.24M ﹤0.01% 1582
2017
Q2 		$581K Sell
6,202
-23,490
-79% -$1.44M ﹤0.01% 2352
2017
Q1 		$1.89M Buy
+29,692
New +$1.8M ﹤0.01% 1781

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Russell Investments Group's CLVS Position: Q1 2022 in Review

Russell Investments Group sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 148,680 shares — an estimated $401K sold.

Russell Investments Group first reported a position in CLVS in Q1 2017 and held it in 12 quarters. The position peaked at $2.84M in Q3 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • Russell Investments Group reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
  • Russell Investments Group sold 148,680 Clovis Oncology, Inc. shares in Q1 2022, an estimated $401K.
  • Russell Investments Group first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 12 quarters.
  • Russell Investments Group's Clovis Oncology, Inc. position peaked at $2.84M in Q3 2017.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Russell Investments Group's 13F filing for Q1 2022, filed 5 May 2022.